Weill Cornell Medicine Urology
Weill Cornell Medicine Urology
Neil H. Bander, M.D.

Neil H. Bander, M.D.

Find a Physician


Quickly search our world-class physicians and faculty by keyword, location and insurance provider.


First Clinical Trial of New Targeted Molecular Therapy in U.S. Takes Aim at Incurable Prostate Cancer

NewYork-Presbyterian and Weill Cornell Medicine clinicians in progress on Phase 1 clinical trial of PSMA-Targeted Therapeutic Agent for the Treatment for Metastatic Prostate Cancer

NewYork-Presbyterian and Weill Cornell Medicine have begun the first clinical trial in the U.S. that uses a small molecule, 177Lu-PSMA-617, to treat men with progressive prostate cancer that has spread beyond the prostate, or is metastatic, and is no longer responding to hormonal therapy.

PSMA radioligand therapy shows promise in clinical study

Therapeutic agent developed by Neil Bander, MD, Weill Cornell Urology Physician Scientist, shows promise in new trials to provide treatment for advanced prostate cancer.


Neil H. Bander

Dr. Bander completed fellowship training in clinical urological oncology under Dr. Willet F. Whitmore, Jr., and an NIH Immunology Training Fellowship in the laboratory of Dr. Lloyd Old, both at Memorial Sloan-Kettering Cancer Center. After coming to NYPH-Weill Cornell, he focused on clinical urological oncology and the development of monoclonal antibodies for targeted cancer therapy. He has directed both a laboratory and translational clinical research program.

Find a Physician FIND A PHYSICIAN

© 2016 Weill Cornell Medicine All rights reserved.